New injection targets tough liver cancer in small early trial
NCT ID NCT07201064
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This early-phase study tests the safety and tolerability of a new drug called SZ1003 in 12 people with advanced liver cancer that has not responded to at least two prior treatments. The main goal is to check for side effects over 24 weeks, while also looking at whether the drug can shrink tumors or control the disease. It is a small, dose-escalation trial to find a safe dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.